

| | |
|--------------------------------|--|
| 1. Record Nr. | UNINA9910812068203321 |
| Titolo | Breakthrough business models : drug development for rare and neglected diseases and individualized therapies : workshop summary / / Theresa Wizemann, Sally Robinson, and Robert Giffin ; Forum on Health Sciences Policy, Institute of Medicine of the National Academies |
| Pubbl/distr/stampa | Washington, D.C., : National Academies Press, 2009 |
| ISBN | 0-309-17816-9 1-282-08355-4 9786612083556 0-309-12089-6 |
| Edizione | [1st ed.] |
| Descrizione fisica | 1 online resource (149 p.) |
| Altri autori (Persone) | WizemannTheresa M RobinsonSally GiffinRobert B |
| Disciplina | 615/.19 |
| Soggetti | Orphan drugs - Government policy - United States Pharmaceutical policy - United States Drugs - Design - United States |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Note generali | Bibliographic Level Mode of Issuance: Monograph |
| Nota di bibliografia | Includes bibliographical references (p. 104-105). |
| Nota di contenuto | Introduction and overview -- Current model for financing drug development : from concept through approval -- The Food and Drug Administration's Orphan Drug Program -- Diverse funding models -- Strategies for facilitating sharing of research materials and data -- Strategies of navigation intellectual property -- Strategies for facilitating clinical trials -- Summary. |
| Sommario/riassunto | "The Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop on June 23, 2008, titled "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies." The purpose of the workshop was to explore innovative strategies for orphan drug development."--P. 3. |